- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Ibrance® | PD-0332991 | PD0332991
palbociclib is an approved drug (FDA (2015), EMA (2016))
Compound class: Synthetic organic
Comment: Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 [6-7,14]. This kinase inhibitor has anti-tumour activity in several tumour models [6-7,9,15-16].
The pharmaceutical formulation contains palbociclib isethionate (PubChem CID 11478676).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: palbociclib
|Palbociclib acts via inhibition of CDK4/6 to dose-dependently reduce phosphorylation of the retinoblastoma protein (Rb) with an IC50 of 30nM  in both MV4-11 and MOLM13 acute myelocytic leukemia (AML) cell lines.|
|Selectivity at enzymes|
|Key to terms and symbols||Click column headers to sort|
|Ligand mentioned in the following text fields|
|CDK4 subfamily overview|